(cilastatin sodium + imipenem + relebactam)
Marketedupdated 2mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.
all catalysts(3)
approval · 3
Jul 16, 2019
approval
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
Jun 4, 2020
approval
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
Dec 9, 2025
approval
RECARBRIO (CILASTATIN SODIUM) — FDA approval
(cilastatin sodium + imipenem + relebactam)
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that